Skip Nav Destination
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
Issue Archive
Table of Contents
STIMULUS REPORTS
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies
Caner Saygin,Gregory Roloff,Christopher N. Hahn,Rakchha Chhetri,Saar Gill,Hany Elmariah,Chetasi Talati,Emma Nunley,Guimin Gao,Aelin Kim,Michael Bishop,Satyajit Kosuri,Soma Das,Deepak Singhal,Parvathy Venugopal,Claire C. Homan,Anna Brown,Hamish S. Scott,Devendra Hiwase,Lucy A. Godley
Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study
Clinical Trials & Observations
Nico Gagelmann,Gerald Georg Wulf,Johannes Duell,Bertram Glass,Pearl van Heteren,Bastian von Tresckow,Monika Fischer,Olaf Penack,Francis Ayuk,Herrmann Einsele,Udo Holtick,Julia Thomson,Peter Dreger,Nicolaus Kröger
CLINICAL TRIALS AND OBSERVATIONS
Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial
Clinical Trials & Observations
G. A. Amos Burke,Luciana Vinti,Edita Kabickova,Auke Beishuizen,Nurdan Tacyildiz,Anne Uyttebroeck,Hyoung Jin Kang,Flavio Luisi,Véronique Minard-Colin,Birgit Burkhardt,Monelle Tamegnon,Steven Sun,Madeliene Curtis,Sanjay Deshpande,Kerri Nottage,Angela Howes,Srimathi Srinivasan,Deepa Bhojwani,Robin Norris,Mitchell Cairo
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
Clinical Trials & Observations
Mohsen S. Elalfy,Mona Hamdy,Amal El-Beshlawy,Fatma S. E. Ebeid,Mohamed Badr,Julie Kanter,Baba Inusa,Amira A. M. Adly,Suzan Williams,Yurdanur Kilinc,David Lee,Caroline Fradette,Anna Rozova,Noemi Toiber Temin,Fernando Tricta,Janet L. Kwiatkowski
HEMATOPOIESIS AND STEM CELLS
Disruption of stem cell niche–confined R-spondin 3 expression leads to impaired hematopoiesis
Antonina V. Kurtova,Melanie Heinlein,Simon Haas,Lars Velten,Gerrit J. P. Dijkgraaf,Elaine E. Storm,Noelyn M. Kljavin,Soufiane Boumahdi,Patricia Himmels,Aurelie Herault,Andrew Mancini,Hartmut Koeppen,Monique Dail,Qingxiang Yan,Jianhuan Zhang,Ute Koch,Freddy Radtke,Zora Modrusan,Ciara Metcalfe,Robert Piskol,Frederic J. de Sauvage
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium
Heather E. Stefanski,Anne Eaton,Christina Baggott,Jenna Rossoff,Michael R. Verneris,Snehit Prabhu,Holly L. Pacenta,Christine L. Phillips,Julie-An Talano,Amy Moskop,Steven P. Margossian,Gary Douglas Myers,Nicole A. Karras,Patrick A. Brown,Muna Qayed,Michelle Hermiston,Prakash Satwani,M. Christa Krupski,Amy K. Keating,Rachel Wilcox,Cara A. Rabik,Vanessa A. Fabrizio,Vasant Chinnabhandar,A. Yasemin Goksenin,Kevin J. Curran,Crystal L. Mackall,Theodore W. Laetsch,Liora M. Schultz
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells
Adam J. Lamble,Regina M. Myers,Agne Taraseviciute,Samuel John,Bonnie Yates,Seth M. Steinberg,Jennifer Sheppard,Alexandra E. Kovach,Brent Wood,Michael J. Borowitz,Maryalice Stetler-Stevenson,Constance M. Yuan,Vinodh Pillai,Toni Foley,Perry Chung,Lee Chen,Daniel W. Lee,Colleen Annesley,Amanda DiNofia,Stephan A. Grupp,Michael R. Verneris,Lia Gore,Theodore W. Laetsch,Deepa Bhojwani,Patrick A. Brown,Michael A. Pulsipher,Susan R. Rheingold,Rebecca A. Gardner,Nirali N. Shah
LYMPHOID NEOPLASIA
SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
Guus J. J. E. Heynen,Francis Baumgartner,Michael Heider,Upayan Patra,Maximilian Holz,Jan Braune,Melanie Kaiser,Isabell Schäffer,Stefanos A. Bamopoulos,Evelyn Ramberger,Arunima Murgai,Yuen Lam Dora Ng,Uta Margareta Demel,Dominik Laue,Sven Liebig,Josefine Krüger,Martin Janz,Axel Nogai,Markus Schick,Philipp Mertins,Stefan Müller,Florian Bassermann,Jan Krönke,Ulrich Keller,Matthias Wirth
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress
Jiro Kikuchi,Nobuyuki Kodama,Masataka Takeshita,Sho Ikeda,Takahiro Kobayashi,Yoshiaki Kuroda,Michihiro Uchiyama,Naoki Osada,Bjarne Bogen,Hiroshi Yasui,Naoto Takahashi,Akiyoshi Miwa,Yusuke Furukawa
Gene expression profiling and FDG-PET radiomics uncover radiometabolic signatures associated with outcome in DLBCL
Saveria Mazzara,Laura Travaini,Francesca Botta,Chiara Granata,Giovanna Motta,Federica Melle,Stefano Fiori,Valentina Tabanelli,Anna Vanazzi,Safaa Ramadan,Tommaso Radice,Sara Raimondi,Giuliana Lo Presti,Mahila E. Ferrari,Barbara Alicja Jereczek-Fossa,Corrado Tarella,Francesco Ceci,Stefano Pileri,Enrico Derenzini
MYELOID NEOPLASIA
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study
Clinical Trials & Observations
Paul G. Kemps,Timo C. E. Zondag,Helga B. Arnardóttir,Nienke Solleveld-Westerink,Jelske Borst,Eline C. Steenwijk,Demi van Egmond,Joost F. Swennenhuis,Ellen Stelloo,Irene Trambusti,Robert M. Verdijk,Carel J. M. van Noesel,Arjen H. G. Cleven,Marijn A. Scheijde-Vermeulen,Marco J. Koudijs,Lenka Krsková,Cynthia Hawkins,R. Maarten Egeler,Jesper Brok,Tatiana von Bahr Greenwood,Karel Svojgr,Auke Beishuizen,Jan A. M. van Laar,Ulrike Pötschger,Caroline Hutter,Elena Sieni,Milen Minkov,Oussama Abla,Tom van Wezel,Cor van den Bos,Astrid G. S. van Halteren
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
RESEARCH LETTERS
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort
Gianluigi Reda,Veronica Mattiello,Anna Maria Frustaci,Andrea Visentin,Francesca Romana Mauro,Idanna Innocenti,Massimo Gentile,Diana Giannarelli,Alessandro Noto,Ramona Cassin,Antonino Neri,Luca Laurenti,Alessandra Tedeschi
Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis
Clinical Trials & Observations
Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists
Clinical Trials & Observations
Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
Clinical Trials & Observations
Suzette Girgis,Shun Xin Wang Lin,Kodandaram Pillarisetti,Raluca Verona,Diego Vieyra,Tineke Casneuf,Damien Fink,Xin Miao,Yang Chen,Tara Stephenson,Arnob Banerjee,Brandi W. Hilder,Jeffery Russell,Jeffrey Infante,Yusri Elsayed,Jennifer Smit,Jenna D. Goldberg
ERRATUM
-
Cover Image
Cover Image
Myeloma cells isolated from extramedullary lesions form cell clusters in culture with hyaluronic acid (HA) under shear stress. Clustered cells highly express the HA receptor CD44, whose engagement with HA was visualized by immunocytochemical staining with HA-binding protein (HABP). The binding of HA to surface CD44 might trigger the homophilic interaction of myeloma cells, which is enhanced by shear stress in the bone marrow microenvironment to serve as a seed of extramedullary disease. See the article by Kikuchi et al.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Advertisement intended for health care professionals